Lista de obras -

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

artículo científico publicado en 2002

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

artículo científico publicado en 2005

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance

artículo científico publicado en 2005

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

artículo científico publicado en 2003

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

artículo científico publicado en 2005

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

artículo científico publicado en 2002

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

artículo científico publicado en 2003

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

artículo científico publicado en 2005

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

artículo científico publicado en 2007

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

artículo científico publicado en 2003

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

artículo científico publicado en 2004

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

artículo científico publicado en 2003

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

artículo científico publicado en 2006

Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

artículo científico publicado en 2004

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model

artículo científico publicado en 2002

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

artículo científico publicado en 2006

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance

artículo científico publicado en 2003

Lista de obras de

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance